论文信息 - Is silence still golden? Mapping the RNAi patent landscape - 字舞流文

Is silence still golden? Mapping the RNAi patent landscape

The field of RNA interference has lately seen its fortunes diminish, but is the situation really that precarious?

[1] A. Fire,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[2] T. Tuschl,et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[3] Public biotech 2006—the numbers , 2007, Nature Biotechnology.

[4] Daniel Jones. Teaming up to tackle RNAi delivery challenge , 2009, Nature Reviews Drug Discovery.

[5] J. Hodgson,et al. Public biotech 2008—the numbers , 2009, Nature Biotechnology.

[6] Robert Langer,et al. On firm ground: IP protection of therapeutic nanoparticles , 2010, Nature Biotechnology.

[7] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[8] Coming to terms. , 2009, Nature biotechnology.

[9] J. Couzin-Frankel. Drug research. Roche exits RNAi field, cuts 4800 jobs. , 2010, Science.

[10] Heidi Ledford. Drug giants turn their backs on RNA interference , 2010, Nature.

[11] Bonnie W McLeod,et al. The 'real world' utility of miRNA patents: lessons learned from expressed sequence tags , 2011, Nature Biotechnology.